Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1999 3
2000 4
2002 2
2003 4
2004 3
2005 7
2006 6
2007 10
2008 9
2009 12
2010 11
2011 4
2012 13
2013 11
2014 7
2015 5
2016 5
2017 5
2018 3
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

111 results
Results by year
Filters applied: . Clear all
Page 1
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X, Ma J, Wang K, Zhang H. Qiu X, et al. Oncotarget. 2017 Jan 3;8(1):1031-1045. doi: 10.18632/oncotarget.13715. Oncotarget. 2017. PMID: 27906680 Free PMC article. Review.
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) has been widely studied; however, the results remain conflicting. ...CONCLUSIONS: 5-ASA has a chemopreve
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflamm …
5-Aminosalicylic acid and chemoprevention: does it work?
Lopez A, Peyrin-Biroulet L. Lopez A, et al. Dig Dis. 2013;31(2):248-53. doi: 10.1159/000353806. Epub 2013 Sep 6. Dig Dis. 2013. PMID: 24030235 Review.
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). Intestinal inflammation is the main risk factor for colorectal cancer (CRC) in IBD. ...More recently, a meta-analysis failed to identify a p
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD).
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. Terdiman JP, et al. Inflamm Bowel Dis. 2007 Apr;13(4):367-71. doi: 10.1002/ibd.20074. Inflamm Bowel Dis. 2007. PMID: 17206695
Published data are conflicting about whether 5-aminosalicylic acid (5-ASA) has chemopreventive properties against IBD-related carcinogenesis. ...However, there was a trend toward a decreased risk of CRC with increasing number of mesalamine
Published data are conflicting about whether 5-aminosalicylic acid (5-ASA) has chemopreventive properties …
5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
Cheng Y, Desreumaux P. Cheng Y, et al. World J Gastroenterol. 2005 Jan 21;11(3):309-14. doi: 10.3748/wjg.v11.i3.309. World J Gastroenterol. 2005. PMID: 15637733 Free PMC article. Review.
The chemopreventive efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) against intestinal tumors has been well established. ...Another hopeful candidate chemoprevention drug for IBD patients is 5-aminosalicylic acid (5-ASA), which …
The chemopreventive efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) against intestinal tumors has been well established. .. …
The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U. Klotz U. Arzneimittelforschung. 2012 Feb;62(2):53-8. doi: 10.1055/s-0031-1299685. Epub 2012 Feb 16. Arzneimittelforschung. 2012. PMID: 22344548 Review.
For more than 30 years mesalazine (5-aminosalicylic acid; 5-ASA) has been used for the treatment of chronic inflammatory bowel disease (IBD) especially in ulcerative colitis (UC). ...There is increasing evidence that 5-ASA also has some therapeu …
For more than 30 years mesalazine (5-aminosalicylic acid; 5-ASA) has been used for the treatment of chronic infl …
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
Giannini EG, Kane SV, Testa R, Savarino V. Giannini EG, et al. Dig Liver Dis. 2005 Oct;37(10):723-31. doi: 10.1016/j.dld.2005.02.012. Dig Liver Dis. 2005. PMID: 16023905 Review.
The analogies between acetyl-salicylic acid and 5-amino-salicylic acid, and the results obtained by using acetyl-salicylic acid as a chemopreventive agent in patients with sporadic colorectal cancer have prompted the study of potential chemop
The analogies between acetyl-salicylic acid and 5-amino-salicylic acid, and the results obtained by using acetyl-salicy …
Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M, Seril DN, Van Gurp J, Geng X, Alvarez J, Minacapelli CD, Gorin S, Das KK, Poplin E, Cheng J, Amenta PS, Das KM. Bajpai M, et al. Dig Dis Sci. 2019 Mar;64(3):740-750. doi: 10.1007/s10620-018-5378-8. Epub 2018 Nov 26. Dig Dis Sci. 2019. PMID: 30478770 Clinical Trial.
BACKGROUND: The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cancer in ulcerative colitis (UC) patients was reported, but the effect on molecular targets in UC colon mucosa is unknown. ...CONCLUSION: This s …
BACKGROUND: The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cance …
Chemoprevention of colorectal neoplasia.
Wakeman C, Keenan J, Eteuati J, Hollington P, Eglinton T, Frizelle F. Wakeman C, et al. ANZ J Surg. 2017 Dec;87(12):E228-E232. doi: 10.1111/ans.13392. Epub 2015 Dec 21. ANZ J Surg. 2017. PMID: 26686322 Review.
There is however a growing awareness of a potential role for chemoprevention in some patient groups. This study aimed to review the literature associated with chemoprevention in colorectal cancer. ...Folic acid, statins, antioxidants, calcium and 5- …
There is however a growing awareness of a potential role for chemoprevention in some patient groups. This study aimed to review the l …
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
Miyoshi J, Yajima T, Shimamura K, Matsuoka K, Okamoto S, Higuchi H, Funakoshi S, Takaishi H, Hibi T. Miyoshi J, et al. Anticancer Res. 2012 Apr;32(4):1193-202. Anticancer Res. 2012. PMID: 22493349
Here we determined the effect of 5-aminosalicylic acid (5-ASA) on COX-2 and 15-PGDH expression and investigated its preventive effect for colorectal cancer (CRC). MATERIALS AND METHODS: HT-29 cells were used in the in vitro experiments. c-Ha-ras transg …
Here we determined the effect of 5-aminosalicylic acid (5-ASA) on COX-2 and 15-PGDH expression and investigated …
5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes.
Koelink PJ, Mieremet-Ooms MA, Corver WE, Wolanin K, Hommes DW, Lamers CB, Verspaget HW. Koelink PJ, et al. Inflamm Bowel Dis. 2010 Mar;16(3):379-89. doi: 10.1002/ibd.21086. Inflamm Bowel Dis. 2010. PMID: 19774649
INTRODUCTION: Epidemiological data suggests that 5-aminosalicylic acid (5-ASA), a nonsteroidal antiinflammatory drug used in the treatment of inflammatory bowel diseases, prevents colorectal cancer development in these patients, although the mechanisms …
INTRODUCTION: Epidemiological data suggests that 5-aminosalicylic acid (5-ASA), a nonsteroidal antiinflammatory …
111 results
Jump to page
Feedback